Weight Loss Medication That Is Not an Injection: What the UK Offers Now

Step 1: Understanding what non-injection options are actually licensed for weight management in the UK

Until June 2026, if you wanted a GLP-1 medicine for weight loss in the UK, an injection was the only route. The Wegovy tablet changed that. Approved by the MHRA on 11 June 2026, it contains semaglutide (the same active ingredient as the Wegovy injection) co-formulated with an absorption enhancer that lets it survive the digestive process and enter the bloodstream. The NHS semaglutide medicines page covers the general profile of semaglutide, and the MHRA's approval confirmed the tablet's licence for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or raised cholesterol.

Orlistat is the other non-injection option. It has been available for longer and works differently: rather than influencing appetite-regulating hormones, it inhibits pancreatic lipase, which means roughly a third of the fat you eat passes through unabsorbed. It is available on prescription and, at lower strength, over the counter at a pharmacy. It does not affect hunger the way GLP-1 medicines do, and its side-effect profile (loose, oily stools if dietary fat is too high) reflects that mechanism directly.

What neither of these is: Rybelsus. Rybelsus is also an oral semaglutide tablet, but it is licensed for type 2 diabetes at doses of 3mg, 7mg and 14mg, not for weight management. The Wegovy tablet's dosing ladder (1.5mg, 4mg, 9mg and 25mg) is entirely separate. If you want a full picture of which non-injection weight loss medications are considered most effective, that page compares the licensed options in detail, including how Rybelsus fits into the wider landscape. That distinction matters if you have seen Rybelsus mentioned online in a weight-loss context.

Step 2: How the Wegovy tablet is taken, and what the trial evidence showed

The dosing schedule starts at 1.5mg once daily and escalates through 4mg and 9mg to a 25mg maintenance dose, spending at least a month at each level. There is one rule about timing that patients consistently say they wished someone had told them upfront: the tablet must be taken first thing in the morning, on a completely empty stomach, with no more than a small sip of plain water. You then wait at least 30 minutes before any food, coffee or other oral medicines. The tablet before the kettle goes on, in other words. That 30-minute window is not a guideline you can quietly shorten, SNAC-based absorption is sensitive to food and drink in a way that injections simply are not.

In the OASIS 4 phase 3 trial (307 adults with obesity or overweight plus at least one weight-related condition, followed for 64 weeks) participants taking the oral semaglutide tablet lost an average of around 13.6% of body weight compared with around 2.4% on placebo. Among those who stuck fully to their regimen, the average reached approximately 17%. The most frequently reported side effects were gastrointestinal: nausea, vomiting and diarrhoea affected a higher proportion of the active group than placebo, though most cases were described as mild to moderate and tended to ease as the body adjusted. The Wegovy tablet does not require refrigeration, which is a practical advantage for travel or anyone without reliable fridge access.

Patients already stable on the 2.4mg weekly injection of Wegovy may, subject to clinical assessment, move directly to the 25mg tablet rather than re-titrating from the beginning, and our page on how to inject weight loss medication explains the administration technique for anyone currently on or considering the injectable route before making that switch. That transition is a prescriber decision, not a self-managed switch.

Step 3: What a consultation looks at before either option is prescribed

A prescriber reviewing a request for non-injection weight loss medication will look at the same core factors regardless of which medicine is on the table. BMI is the starting point, but it is not the whole picture. Current medicines matter significantly for the Wegovy tablet: because it is taken with a small sip of water and requires a 30-minute gap before anything else, patients on multiple morning medications need to discuss timing carefully. Women using the oral contraceptive pill who are also considering tirzepatide injections should note that additional contraception is recommended during the early treatment period, though that specific interaction evidence relates to the injectable GLP-1 tirzepatide, not to oral semaglutide.

History of pancreatitis, certain thyroid conditions and pregnancy or plans to conceive are standard contraindications that the prescriber will screen for. Neither the Wegovy tablet nor orlistat is licensed for use during pregnancy or breastfeeding, and neither is recommended for people trying to conceive. Anyone under 18 is outside the licensed age range for both. For a broader look at how the injectable weight loss medicines compare in terms of evidence and eligibility, that page sets out the clinical picture clearly.

At nume, every consultation is read by a GPhC-registered Independent Prescriber (a named clinician, not automated screening) on the same day it is submitted. Our clinical team reviews medical history, current medication and verified weight before any prescription is issued. Our FAQs page covers the most common practical questions patients ask before starting.

The cost and NHS access picture for non-injection weight loss medicines

The Wegovy tablet is not currently available on the NHS: a NICE appraisal would need to follow the MHRA approval before NHS commissioning could begin. For now, it is private prescription only. NICE's recommendation for the Wegovy injection (TA875) gives a sense of the appraisal process and the kind of eligibility criteria that tend to follow, though the tablet would go through a separate assessment. Orlistat is available on the NHS, though access varies by GP practice and local formulary.

Private prescription costs for the Wegovy tablet will vary between providers. For context on how to think about pricing for prescription weight loss medicines more broadly (including what a headline price often does and doesn't include) the weight loss treatment overview is a useful reference. The short version: a legitimate price for a prescription medicine always includes the clinical assessment, not just the medicine itself. Providers who appear unusually cheap are worth scrutinising carefully, and if you are unsure which treatments are genuine licensed options, our guide to weight loss injection medication names lists the approved products so you can cross-check what you are being offered. The MHRA has warned consistently about fake weight loss products sold through unverified online sellers and social media, and that risk applies to newer, in-demand products quickly.

If you are weighing up whether an injection-free route suits your situation, or you want to understand how the tablet compares to the full range of weight loss injection treatments in practical terms, our dedicated page covering weight loss injectable medication sets out the options clearly before you decide. Speak to our prescribers through a free consultation at the treatments page, you'll get a same-day clinical review and a clear answer on what is suitable for you.